The concept that subclinical insulin secretory defects may affect linear growth independently from hyperglycemia has been suggested by a small-sized study in CF (20), but further evidence arises from studies in type 1 diabetes and in healthy subjects. This evidence concerns the gene INS and cystic fibrosis.